The document discusses when a patient can be considered empowered. It provides several criteria for an empowered patient, including having control over their own health decisions, knowing their rights, and actively participating in medical decision making. It then presents a self-assessment survey for patients to rate themselves on various empowerment factors and aspects of health literacy. Completing the assessment regularly allows patients to identify areas for improvement and work towards a higher level of empowerment over time.
The practice of anesthesia and sedation continues to expand beyond the operating room and now includes the gastroenterology suite, magnetic resonance imaging suites, and the cardiac catheterization laboratory. Non-anesthesiologists frequently administer sedation, in part because of a lack of available anesthesiologists and economic aspect, which emphasizes the safety of sedation. The Joint Commission International (JCI) set a standard responding to this issue indicating that qualified individuals who have drug and monitoring knowledge as well as airway management skills can only administer sedating agents.
Credentialing refers to the process of collection and verification of the evidences of credentials of a doctor who is to be given the responsibility of
treating patients in the hospital. The process
ensures the authenticity of the details provided
by the healthcare practitioner or doctor.
This Hospital Skills Program (HSP) module has been developed to support the professional development of doctors working in a hospital generalist role in NSW hospitals.
Doctors participating in the HSP will have at least two years of clinical postgraduate experience and not be currently participating in a specialist vocational training program.
This HSP module has been developed by CETI on behalf of NSW Health as part of the Hospital Skills Program for generalist doctors. It aims to guide doctors, their employers and educators with regard to learning and professional development needs, workplace responsibilities and clinical tasks.
This module is one of several that have been developed by CETI to support the implementation of the HSP.
Patient Experience Defined. Patient experience encompasses the range of interactions that patients have with the health care system, including their care from health plans, and from doctors, nurses, and staff in hospitals, physician practices, and other health care facilities.
nursing process is the base or heart of complete nursing and nursing process gives the framework for the nurses in giving care to the patient the knowledge of nursing process is must to become a licensed nurse or to practice nursing this ppt give nurses a brief idea what all thing are including in nursing process and to determine efficiency, knowledge, skills and attitude of personnel and can make best use of their skills into clinical practice.
Abstract
To assess the patient satisfaction level in emergency
department of a level 1Trauma Centre in India.
Shallu Chauhan, Dr.Deepak AgrawaL.
JPN Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi-110029, India
Introduction
Patient satisfaction is an important indicator of the quality of care and service delivery in the
emergency department (ED). The objective of this study was to evaluate patient satisfaction
level in the E.D. of a level 1 Trauma Centre,AIIMS,New Delhi.To determine the effects of
actual waiting time,perception of waiting time,information delivery and expressive quality on
patient satisfaction.
Methods
This study was carried out for 2 months during all shifts mostly for those patients who triaged
as green.We made two groups:1) control group{ not explained anything to the patient} and
2) test group{patient explained for time management & treatment}. Patients/relatives were
asked to complete the questionnaire prior to discharge. For the first month, eight questions
were based on descripitve information were distributed to the control group { questions
including explanation of procedures to the patient,communication of staffs,problems faced
by patient/relatives, and overall patient satisfaction level}.Then, following second month
another study questionnaire included 11 questions based on a Likert scale concerning
waiting time{ie,overall time management,waiting for X-ray or C.T,scan,review by doctor, for
discharge & treatment},promptness & behaviour of staff and cleaniness of hospital given to
the test group.
Observation
Ninety patients who attended our ED were included in this study.The perception that waiting
times for placebo injection & T/t were less than expected was associated with a positive
overall satisfaction rating for the ED encounter[p is 0.033] as compared to actual waiting
time.Actual waiting time were not predictive of overall patient satisfaction. The highest
satisfaction rates were observed in cleaniness of hospital in both the groups and most of them
rated it as very good. For overall treatment, in control group 34% rated as poor & fair and
67% rated as good and very good,whereas in test group only 22% rated as poor and fair
but78% rated as very good and excellent.At the same time,both the groups were rated as
good for overall time management but they were not satisfy with the time taken by doctor
to review the reports and 33% rated as fair in control group and 22% rated as fair in test
goup.The assigned waiting time for particular physician to review a report was 60minutes
but average time taken to consult a particular physician was >60mins which mostly occur
in control group.The overall satisfaction rate was dependent on the mean waiting time. The
highest waiting time for a low rate of satisfaction of patient was 180minutes and for very
good level of satisfaction was just 15minutes. In control group,30% and 17% of patients
rated as fair and poor
iemsa Stain report; Table of ContentsIntroductionObjectives of Giemsa stainPrincipleReagents UsedProcedureStaining procedure 1: Thin Film stainingStaining Procedure 2: Thick Film StainingResultsInterpretation/ConclusionApplications Giemsa stainAdvantagesLimitationsReferencesFour Charged in Plot to Kidnap an Iranian Journalist in New YorkIntroductionGiemsa stain was a name adopted from a Germany Chemist scientist, for his application of a combination of reagents in demonstrating the presence of parasites in malaria.It belongs to a group of stains known as Romanowsky stains. These are neutral stains made up of a mixture of oxidized methylene blue, azure, and Eosin Y and they performed on an air-dried slide that is post-fixed with methanol. Romanowsky stains are applied in the differentiation of cells, pathological examinations of samples like blood and bone marrow films and demonstration of parasites e.g malaria. There are four types of Romanoswsky stains:Giemsa stainJenner StainWright stainMay-Grunwald StainLeishman stainObjectives of Giemsa stainTo accurately prepare the Giemsa stain stock solutionTo stain and identify blood cellsTo differentiate blood cells nuclei from the cytoplasmPrincipleGiemsa stain is a gold standard staining technique that is used for both thin and thick smears to examine blood for malaria parasites, a routine check-up for other blood parasites and to morphologically differentiate the nuclear and cytoplasm of Erythrocytes, leucocytes and Platelets and parasites.Like any type of Romanowsky stains, it composed of both the Acidic and Basic dyes, in relation to affinities of acidity and basicity for blood cells. Azure and methylene blue, a basic dye binds to the acid nucleus producing blue-purple color. Eosin is an acidic dye that is attracted to the cytoplasm and cytoplasmic granules which are alkaline-producing red coloration. The stain must be buffered with water to pH 6.8 or 7.2, to precipitate the dyes to bind simple materials.Classically, Giemsa stain is a differential stain which is made up of a combination of reagents (Azure, Methylene blue, and Eosin dye) used widely in cytogenetics and histopathology for the diagnosis of:Malaria, spirochetes and other blood parasitesChlamydia trachomatis inclusion bodiesBorrelia sppYersinia pestisHistoplasma sppPneumocystis jiroveci cystsReagents UsedMethanolGiemsa powderGlycerinWater (Buffer)ProcedurePreparation of the Giemsa Stain Stock solution (500ml)Into 250ml of methanol, add 3.8g of Giemsa powder and dissolve.Heat the solution up to ~60oCThen, add 250ml of glycerin to the solution, slowly.Filter the solution and leave it to stand for about 1-2 months before use.Preparation of Working solutionAdd 10ml of stock solution to 80ml of distilled water and 10ml of methanolStaining procedure 1: Thin Film stainingOn a clean dry microscopic glass slide, make a thin film of the specimen (blood) and leave to air dry.dip the smear (2-3 dips) into pure methanol for fixation of the smear, lea
The practice of anesthesia and sedation continues to expand beyond the operating room and now includes the gastroenterology suite, magnetic resonance imaging suites, and the cardiac catheterization laboratory. Non-anesthesiologists frequently administer sedation, in part because of a lack of available anesthesiologists and economic aspect, which emphasizes the safety of sedation. The Joint Commission International (JCI) set a standard responding to this issue indicating that qualified individuals who have drug and monitoring knowledge as well as airway management skills can only administer sedating agents.
Credentialing refers to the process of collection and verification of the evidences of credentials of a doctor who is to be given the responsibility of
treating patients in the hospital. The process
ensures the authenticity of the details provided
by the healthcare practitioner or doctor.
This Hospital Skills Program (HSP) module has been developed to support the professional development of doctors working in a hospital generalist role in NSW hospitals.
Doctors participating in the HSP will have at least two years of clinical postgraduate experience and not be currently participating in a specialist vocational training program.
This HSP module has been developed by CETI on behalf of NSW Health as part of the Hospital Skills Program for generalist doctors. It aims to guide doctors, their employers and educators with regard to learning and professional development needs, workplace responsibilities and clinical tasks.
This module is one of several that have been developed by CETI to support the implementation of the HSP.
Patient Experience Defined. Patient experience encompasses the range of interactions that patients have with the health care system, including their care from health plans, and from doctors, nurses, and staff in hospitals, physician practices, and other health care facilities.
nursing process is the base or heart of complete nursing and nursing process gives the framework for the nurses in giving care to the patient the knowledge of nursing process is must to become a licensed nurse or to practice nursing this ppt give nurses a brief idea what all thing are including in nursing process and to determine efficiency, knowledge, skills and attitude of personnel and can make best use of their skills into clinical practice.
Abstract
To assess the patient satisfaction level in emergency
department of a level 1Trauma Centre in India.
Shallu Chauhan, Dr.Deepak AgrawaL.
JPN Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi-110029, India
Introduction
Patient satisfaction is an important indicator of the quality of care and service delivery in the
emergency department (ED). The objective of this study was to evaluate patient satisfaction
level in the E.D. of a level 1 Trauma Centre,AIIMS,New Delhi.To determine the effects of
actual waiting time,perception of waiting time,information delivery and expressive quality on
patient satisfaction.
Methods
This study was carried out for 2 months during all shifts mostly for those patients who triaged
as green.We made two groups:1) control group{ not explained anything to the patient} and
2) test group{patient explained for time management & treatment}. Patients/relatives were
asked to complete the questionnaire prior to discharge. For the first month, eight questions
were based on descripitve information were distributed to the control group { questions
including explanation of procedures to the patient,communication of staffs,problems faced
by patient/relatives, and overall patient satisfaction level}.Then, following second month
another study questionnaire included 11 questions based on a Likert scale concerning
waiting time{ie,overall time management,waiting for X-ray or C.T,scan,review by doctor, for
discharge & treatment},promptness & behaviour of staff and cleaniness of hospital given to
the test group.
Observation
Ninety patients who attended our ED were included in this study.The perception that waiting
times for placebo injection & T/t were less than expected was associated with a positive
overall satisfaction rating for the ED encounter[p is 0.033] as compared to actual waiting
time.Actual waiting time were not predictive of overall patient satisfaction. The highest
satisfaction rates were observed in cleaniness of hospital in both the groups and most of them
rated it as very good. For overall treatment, in control group 34% rated as poor & fair and
67% rated as good and very good,whereas in test group only 22% rated as poor and fair
but78% rated as very good and excellent.At the same time,both the groups were rated as
good for overall time management but they were not satisfy with the time taken by doctor
to review the reports and 33% rated as fair in control group and 22% rated as fair in test
goup.The assigned waiting time for particular physician to review a report was 60minutes
but average time taken to consult a particular physician was >60mins which mostly occur
in control group.The overall satisfaction rate was dependent on the mean waiting time. The
highest waiting time for a low rate of satisfaction of patient was 180minutes and for very
good level of satisfaction was just 15minutes. In control group,30% and 17% of patients
rated as fair and poor
iemsa Stain report; Table of ContentsIntroductionObjectives of Giemsa stainPrincipleReagents UsedProcedureStaining procedure 1: Thin Film stainingStaining Procedure 2: Thick Film StainingResultsInterpretation/ConclusionApplications Giemsa stainAdvantagesLimitationsReferencesFour Charged in Plot to Kidnap an Iranian Journalist in New YorkIntroductionGiemsa stain was a name adopted from a Germany Chemist scientist, for his application of a combination of reagents in demonstrating the presence of parasites in malaria.It belongs to a group of stains known as Romanowsky stains. These are neutral stains made up of a mixture of oxidized methylene blue, azure, and Eosin Y and they performed on an air-dried slide that is post-fixed with methanol. Romanowsky stains are applied in the differentiation of cells, pathological examinations of samples like blood and bone marrow films and demonstration of parasites e.g malaria. There are four types of Romanoswsky stains:Giemsa stainJenner StainWright stainMay-Grunwald StainLeishman stainObjectives of Giemsa stainTo accurately prepare the Giemsa stain stock solutionTo stain and identify blood cellsTo differentiate blood cells nuclei from the cytoplasmPrincipleGiemsa stain is a gold standard staining technique that is used for both thin and thick smears to examine blood for malaria parasites, a routine check-up for other blood parasites and to morphologically differentiate the nuclear and cytoplasm of Erythrocytes, leucocytes and Platelets and parasites.Like any type of Romanowsky stains, it composed of both the Acidic and Basic dyes, in relation to affinities of acidity and basicity for blood cells. Azure and methylene blue, a basic dye binds to the acid nucleus producing blue-purple color. Eosin is an acidic dye that is attracted to the cytoplasm and cytoplasmic granules which are alkaline-producing red coloration. The stain must be buffered with water to pH 6.8 or 7.2, to precipitate the dyes to bind simple materials.Classically, Giemsa stain is a differential stain which is made up of a combination of reagents (Azure, Methylene blue, and Eosin dye) used widely in cytogenetics and histopathology for the diagnosis of:Malaria, spirochetes and other blood parasitesChlamydia trachomatis inclusion bodiesBorrelia sppYersinia pestisHistoplasma sppPneumocystis jiroveci cystsReagents UsedMethanolGiemsa powderGlycerinWater (Buffer)ProcedurePreparation of the Giemsa Stain Stock solution (500ml)Into 250ml of methanol, add 3.8g of Giemsa powder and dissolve.Heat the solution up to ~60oCThen, add 250ml of glycerin to the solution, slowly.Filter the solution and leave it to stand for about 1-2 months before use.Preparation of Working solutionAdd 10ml of stock solution to 80ml of distilled water and 10ml of methanolStaining procedure 1: Thin Film stainingOn a clean dry microscopic glass slide, make a thin film of the specimen (blood) and leave to air dry.dip the smear (2-3 dips) into pure methanol for fixation of the smear, lea
Decision Point OneBegin Zoloft 50 mg orally dailyBegin Zoloft LinaCovington707
Decision Point One
Begin Zoloft 50 mg orally dailyBegin Zoloft 50 mg orally daily
RESULTS OF DECISION POINT ONE
· Client returns to clinic in four weeks
· Client informs you that he has no tightness in chest, or shortness of breath
· Client states that he noticed decreased worries about work over the past 4 or 5 days
· HAM-A score has decreased to 18 (partial response)
Decision Point Two
Increase dose to 75 mg orally daily
RESULTS OF DECISION POINT TWO
· Client returns to clinic in four weeks
· Client reports an even further reduction in his symptoms
· HAM-A score has now decreased to 10. At this point- continue current dose (61% reduction in symptoms)
Decision Point Three
Maintain current dose
Guidance to Student
At this point, it may be appropriate to continue client at the current dose. It is clear that the client is having a good response (as evidenced by greater than a 50% reduction in symptoms) and the client is currently not experiencing any side effects, the current dose can be maintained for 12 weeks to evaluate full effect of drug. Increasing drug at this point may yield a further decrease in symptoms, but may also increase the risk of side effects. This is a decision that you should discuss with the client. Nothing in the client’s case tells us that we should consider adding an augmentation agent at this point as the client is demonstrating response to the drug. Avoid polypharmacy unless symptoms cannot be managed by a single drug.
Generalized Anxiety Disorder
Middle-Aged White Male With Anxiety
Anxiety
BACKGROUND INFORMATION
The client is a 46-year-old white male who works as a welder at a local steel fabrication factory. He presents today after being referred by his PCP after a trip to the emergency room in which he felt he was having a heart attack. He stated that he felt chest tightness, shortness of breath, and feeling of impending doom. He does have some mild hypertension (which is treated with low sodium diet) and is about 15 lbs. overweight. He had his tonsils removed when he was 8 years old, but his medical history since that time has been unremarkable. Myocardial infarction was ruled out in the ER and his EKG was normal. Remainder of physical exam was WNL.
He admits that he still has problems with tightness in the chest and episodes of shortness of breath- he now terms these “anxiety attacks.” He will also report occasional feelings of impending doom, and the need to “run” or “escape” from wherever he is at.
In your office, he confesses to occasional use of ETOH to combat worries about work. He admits to consuming about 3-4 beers/night. Although he is single, he is attempting to care for aging parents in his home. He reports that the management at his place of employment is harsh, and he fears for his job. You administer the HAM-A, which yields a score of 26.
Client has never been on any type of psychotropic medication.
MENTAL STATUS EXAM
The client is alert, oriented to person, place, time, and ev ...
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
ROJOSON-PEP-TALK: When is a Patient Empowered (Pre-session Recording) - June 2021
1. Empowerment
objective - for
laypeople to
know how to do
self-assessment
on Patient
Empowerment
and to do
continual
improvement.
When do you
say a patient
is
empowered?
2. In my first 2 PEP TALKs in this module on Patient
Empowerment, I have discussed what is Patient
Empowerment and what are the strategies to be
empowered as a patient.
In this PEP TALK, I will answer the question when
do you say a patient is empowered.
I will discuss how a patient can do a self-
assessment on Patient Empowerment and how to
do continual improvement until utmost
empowerment is attained.
When do you
say a patient
is
empowered?
3. When is a patient said to be empowered?
Here are the general answers:
A patient is said to be empowered if he/she gains
full control over decisions and actions affecting his
/ her personal health.
When do you
say a patient
is
empowered?
4. When is a patient said to be empowered?
Here are the general answers:
A patient is said to be empowered if he/she knows
and exercises his/her rights as a patient in getting
the highest attainable standards of health through
the quality and safe services to be provided from
the health care professionals and institutions that
he/she seeks or consults.
When do you
say a patient
is
empowered?
5. When is a patient said to be empowered?
Here are the general answers:
A patient is said to be empowered if he/she knows
how to participate actively and fully with
attending health care professionals in the decision-
making regarding his/her health concerns and
issues.
When do you
say a patient
is
empowered?
6. When is a patient said to be empowered?
Here are the general answers:
A patient is said to be empowered if he/she has
cultivated competencies in managing his own
health within his/her capacity and capability and
within his/her environmental and cultural context.
When do you
say a patient
is
empowered?
7. When is a patient said to be empowered?
To have more quantifiable or measurable answers
to the question, when is a patient said to be
empowered, I came out with a rating scale.
Note: this is my own creation – this constitutes my
Thoughts, Perceptions, Opinions and
Recommendations.
I am open to suggestions for improvement.
When do you
say a patient
is
empowered?
8. Self-assessment of My Level of
Patient Empowerment
A ROJoson Rating Scale
16 items
When do you
say a patient
is
empowered?
9. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I have control over decisions and actions affecting
my personal health.
0 – No control whatsoever
1 – minimal
2 – moderate
3 – great to greatest
When do you
say a patient
is
empowered?
10. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I know my rights as a patient in deciding for my
health.
0 – don’t know any right
1 – Know one (1) to three (3) rights at least
2 – Know four (4) to five (5) rights at least
3 – Know more than five (5) rights
When do you
say a patient
is
empowered?
11. Rights of a Patient for Empowerment
Quality Health Care Services
• Patient-centered
• Equitable
• Safe
• Effective
• Efficient
• Timely
• Integrated
When do you
say a patient
is
empowered?
12. Rights of a Patient for Empowerment
Quality Health Care Services (particularly from a
hospital):
· Quality and safe health care in accordance with
generally approved medical principles
· Respect and dignity without discrimination
· Participation in care decisions
When do you
say a patient
is
empowered?
13. Rights of a Patient for Empowerment
Quality Health Care Services (particularly from a
hospital):
· Informed consent and informed refusal without
prejudice to continuing health care
· Second opinion from alternate health care
professionals of choice
· Privacy and confidentiality of personal
information subject to applicable laws
When do you
say a patient
is
empowered?
14. Rights of a Patient for Empowerment
Quality Health Care Services (particularly from a
hospital):
· Availment of benefits and privileges in
accordance with government regulations and to be
billed accurately
· Complaint about the care and services provided
without fear of reprisal
When do you
say a patient
is
empowered?
15. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I exercise and demand my rights as a patient in
deciding for my own health regardless of the
advice of my relatives and significant others.
0 – never
1 – sometimes
2 – most of the time
3 – all the time
When do you
say a patient
is
empowered?
16. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I exercise and demand my rights as a patient in
deciding for my own health regardless of the
advice of my physicians and other health care
professionals.
0 – never
1 – sometimes
2 – most of the time
3 – all the time
When do you
say a patient
is
empowered?
17. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I participate in the decision-making on my health
concerns and issues with my physicians and other
health care professionals that I consult.
0 – never
1 – sometimes
2 – most of the time
3 – all the time
When do you
say a patient
is
empowered?
18. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I have an intentional living written plan on how to
live full and contented.
0 – don’t have one
1 – have one but not being implemented
2 – have one but not being consistently and
regularly implemented and evaluated
3 – have one being implemented and evaluated
regularly
When do you
say a patient
is
empowered?
19. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I have a healthy lifestyle written plan to keep
myself healthy as much and as long as possible.
0 – don’t have one
1 – have one but not being implemented
2 – have one but not being consistently and
regularly implemented and evaluated
3 – have one being implemented and evaluated
regularly
When do you
say a patient
is
empowered?
20. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I have an advance health care directive
(instructions on how to manage me when I am
terminally ill).
0 – don’t have one
1 – have one but not being implemented
2 – have one but not being consistently and
regularly implemented and evaluated
3 – have one being implemented and evaluated
regularly
When do you
say a patient
is
empowered?
21. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I know how to do cardiopulmonary resuscitation.
0 – don’t know
1 – have an idea but don’t know how to do it
2 – know how to do it but have not practiced /
done it
3 – have practiced / applied it
When do you
say a patient
is
empowered?
22. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I know how to control bleeding from a wound in
the body surface.
0 – don’t know
1 – have an idea but don’t know how to do it
2 – know how to do it but have not practiced /
done it
3 – have practiced / applied it
When do you
say a patient
is
empowered?
23. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I know how to do first aid for medical emergencies
on myself and others.
0 – don’t know at all
1 – know how to do first aid for one to 2 medical
emergencies
2 – know how to do first aid for 3 to 5 medical
emergencies
3 – know how to do first aid for more than 5
medical emergencies
When do you
say a patient
is
empowered?
24. List of some basic medical emergencies where
laypeople should know how to do first aid:
• Cardiopulmonary resuscitation
• Airway promotion
• Control of bleeding from a surface wound
• Splinting (for fractures)
• Poisoning
• Fainting
• High grade fever
• Others
When do you
say a patient
is
empowered?
25. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I have attended and completed a basic course
(either formal or tutorial or in combination) on
strategies in health maintenance and restoration
of health.
0 – have not attended a basic course whatsoever
1 – have attended sporadically
2 – have attended but not a complete course
3 – have completed a basic course
When do you
say a patient
is
empowered?
26. List of some topics in the basic course in health
maintenance and restoration for health for
laypeople:
• Patient’s Rights in Patient Empowerment
• Patient Management Process
• Realities, inclusive of peculiarities,
idiosyncrasies and limitations of medicine, in
administration and management of health care
• Individual Health Management
• Medical Emergencies and First-Aid
When do you
say a patient
is
empowered?
27. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I know the diagnostic processes in the
management of a patient.
0 – don’t know at all
1 – know a little / minimum amount
2 – know some / moderate amount
3 – know fully
When do you
say a patient
is
empowered?
28. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I know the treatment processes in the
management of a patient.
0 – don’t know at all
1 – know a little / minimum amount
2 – know some / moderate amount
3 – know fully
When do you
say a patient
is
empowered?
29. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I know the peculiarities, idiosyncrasies and
limitations of medicine and medical practice such
as inexactness and differing methods and
mindsets.
0 – don’t know at all
1 – know a little / minimum amount
2 – know some / moderate amount
3 – know fully
When do you
say a patient
is
empowered?
30. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
I am interested to attend and complete a Patient
Empowerment course to be offered by ROJoson.
0 – not interested at all because I don’t need
further improvement
1 – interested but will attend sporadically
2 –interested but will attend more than 50% of the
course but not the full course
3 – interested in the full course
When do you
say a patient
is
empowered?
31. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
After the accomplishing the rating scale, there are ranges of
scores that classify different levels of Patient Empowerment.
A sample key (note: this is subjective and needs validation):
Key:
Lowest level = 0-15
Low level = 16-32
Moderate level = 33-39
High level = 40-47
Highest level = 48
When do you
say a patient
is
empowered?
32. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
What is more important is to aim for a score of at
least 2 in each statement to have at least a
moderate level of Patient Empowerment.
The ultimate aim, with progressive development,
is a high level, if not a highest level, of Patient
Empowerment.
When do you
say a patient
is
empowered?
33. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
It must be emphasized that one does not have to
feel bad or ashamed if the high level of Patient
Empowerment is not there yet or has not been
achieved. Because in reality, it is not easy.
What is more than important is to know one’s gaps
or deficiencies after the self-assessment; then,
make a plan and a resolve to fill the gaps and to go
to a higher level of Patient Empowerment.
When do you
say a patient
is
empowered?
34. Self-assessment of My Level of Patient Empowerment
A ROJoson Rating Scale
It goes without saying, a self-assessment should be
repeated after the first and at planned intervals
(say 6 months to one year) until one has achieved
a high level, if not the highest level, of Patient
Empowerment.
When do you
say a patient
is
empowered?
35. Online Form:
Self-assessment of My Level of Patient
Empowerment
https://formfaca.de/sm/5LREYTStM
When do you
say a patient
is
empowered?
36. Empowerment
objective - for
laypeople to
know how to do
self-assessment
on Patient
Empowerment
and to do
continual
improvement.
When do you
say a patient
is
empowered?